Key facts
- inSoma Bio’s last known valuation is $18.7M (May 2024).
- It has raised $7.8M across 3 recorded rounds; the latest was Seed Round ($2.7M) in Sep 2025.
- Notable investors include Y Combinator, US National Science Foundation, MedTech Innovator, National Institutes of Health, Makai VC — 23 tracked in total.
- inSoma Bio has filed 10 Form Ds with the SEC since 2020, most recently May 2024 ($2.7M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for inSoma Bio
Funding rounds
3 roundsAbout inSoma Bio
Developer of bioengineered reconstructive biomaterials designed to enable the use of a person's tissue in surgical procedures. The company offers protein-based scaffolds with thermal responsiveness and genetic engineering for structural support and tissue integration, enabling reconstructive surgeons to provide patients with alternatives to synthetic implants that promote natural tissue repair and adaptability.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2018
- Employees
- 10
- Website
- insomabio.com/
- Ownership
- Privately Held (backing)
inSoma Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in inSoma Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on inSoma Bio in its N-PORT filings yet. We sweep new filings monthly.